Published in Blood on December 01, 1997
The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer (2000) 1.33
IgA function--variations on a theme. Immunology (2004) 0.91
Cloning and characterization of an immunoglobulin A Fc receptor from cattle. Immunology (2004) 0.90
IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med (2013) 0.88
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding. MAbs (2015) 0.81
Identification and characterization of macaque CD89 (immunoglobulin A Fc receptor). Immunology (2004) 0.81
Immunoglobulin A: A next generation of therapeutic antibodies? MAbs (2011) 0.81
IgA and IgA-specific receptors in human disease: structural and functional insights into pathogenesis and therapeutic potential. Springer Semin Immunopathol (2006) 0.81
A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. MAbs (2015) 0.78
Monocyte CD64 or CD89 targeting by surfactant protein D/anti-Fc receptor mediates bacterial uptake. Immunology (2006) 0.78
Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica (2012) 0.78
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy. Bioengineering (Basel) (2017) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
A gene expression map for Caenorhabditis elegans. Science (2001) 9.74
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Immunosuppressive effects of apoptotic cells. Nature (1997) 7.03
Compulsory averaging of crowded orientation signals in human vision. Nat Neurosci (2001) 5.47
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Metabolism of vitamin D3-3H in human subjects: distribution in blood, bile, feces, and urine. J Clin Invest (1967) 3.69
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum (1998) 3.41
Biologically active metabolite of vitamin D3 from bone, liver, and blood serum. J Lipid Res (1966) 3.39
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res (1994) 2.96
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis (2001) 2.69
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis (2004) 2.48
A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol (1991) 2.48
Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today (1989) 2.47
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A (1997) 2.45
The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J (1997) 2.34
IgA and the IgA Fc receptor. Trends Immunol (2001) 2.05
On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest (1992) 2.04
IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev (1998) 1.98
In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum (1997) 1.95
Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood (1998) 1.93
Normal function and lack of fibronectin accumulation in kidneys of Clara cell secretory protein/uteroglobin deficient mice. Am J Kidney Dis (1999) 1.89
Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol (1984) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Cloning and characterization of AFX, the gene that fuses to MLL in acute leukemias with a t(X;11)(q13;q23). Oncogene (1997) 1.80
Molecular basis for a polymorphism of human Fc gamma receptor II (CD32). J Exp Med (1990) 1.79
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med (1996) 1.74
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax (2004) 1.69
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Joint and connective tissue ultrasonography--a rheumatologic bedside procedure? A German experience. Arthritis Rheum (1995) 1.66
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol (2001) 1.64
Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis (2003) 1.64
Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int (1995) 1.63
Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis (2001) 1.63
The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol (2001) 1.62
IgG receptor polymorphisms: risk factors for disease. Immunogenetics (1998) 1.59
SLE--a disease of clearance deficiency? Rheumatology (Oxford) (2005) 1.59
Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum (1993) 1.53
Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol (1990) 1.52
The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Mol Immunol (2001) 1.51
Studies on experimental autoimmune thymitis in guinea-pigs. Clin Exp Immunol (1969) 1.50
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol (1992) 1.48
Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding. J Biol Chem (2001) 1.48
Clinical significance of IgG Fc receptors and Fc gamma R-directed immunotherapies. Immunol Today (1997) 1.48
In vitro and in vivo effect of glucocorticoids on IgE and IgG subclass secretion. Clin Exp Allergy (1994) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation (2001) 1.46
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum (1991) 1.45
CD4 positive peripheral T cells from patients with systemic lupus erythematosus (SLE) are clonally expanded. Lupus (2001) 1.44
Gp130 and ras mediated signaling in human plasma cell line INA-6: a cytokine-regulated tumor model for plasmacytoma. Hematol J (2001) 1.43
Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells. J Immunol (1997) 1.42
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42
Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol (1989) 1.41
Inflammation in autoimmunity: receptors for IgG revisited. Trends Immunol (2001) 1.41
Solution structure of a mammalian PCB-binding protein in complex with a PCB. Nat Struct Biol (1995) 1.40
Inappropriate emergency department visits. Ann Emerg Med (1985) 1.40
[Flucticasone propionate is safe in recommended doses]. Lakartidningen (1997) 1.39
A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells. Oncogene (1999) 1.39
Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis (2002) 1.39
Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis (1994) 1.37
Metabolism of tritiated vitamin D3 in familial vitamin D-resistant rickets with hypophosphatemia. J Pediatr (1967) 1.37
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochem J (1990) 1.33
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis (2006) 1.32
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonized with polyclonal human IgG1 and IgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2. J Immunol (1993) 1.29
Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun (2006) 1.29
Tetraspanin microdomains in immune cell signalling and malignant disease. Tissue Antigens (2004) 1.28
Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum (1993) 1.27
Etiopathogenesis of systemic lupus erythematosus. Immunol Today (2000) 1.26
Identification of a new hepatitis B virus (HBV) genotype from Brazil that expresses HBV surface antigen subtype adw4. J Gen Virol (1993) 1.26
Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26
The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activitor of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem (1998) 1.25
Fc gamma receptor IIa (CD32) heterogeneity in patients with recurrent bacterial respiratory tract infections. J Infect Dis (1994) 1.25
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25